Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run
Coverage (6)
-
-
-
-
-
-
Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run Fierce Biotech · 1d ago broke it first
Where it stands
- Velocity & Diffusion: Coverage escalated across 6 distinct news outlets with 6 published articles, achieving a live velocity of 4.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
"Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run" developed substantial multi-source reporting across the Business sector, tracked across 6 distinct newsrooms by Newsylist.
Key reporting was led by WSJ, Investor's Business Daily, Reuters and Yahoo Finance. Coverage velocity and cross-outlet momentum were measured using Newsylist open coverage telemetry.
Synthesized from multi-source international reporting and live coverage telemetry under Newsylist open intelligence methodology.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 48m ago.
Answered
What drove coverage for Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run?
Coverage spiked when 6 independent newsrooms published 6 verified reports during this coverage cycle.
How did Newsylist track this trend?
Newsylist monitored article arrival rates, source diversity, and cross-outlet validation in real time.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.